In HCC, elevated GEF–H1 expression strongly correlates with poor clinical outcomes [8], where it enhances cellular motility through RhoA–ROCK–myosin light chain (MLC) pathway activation [217] (Table 2). Here, ARHGEF2 is linked to hepatocellular carcinoma.